Short answer
Tyra Biosciences, Inc. (TYRA) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$46M
- −62.1% YoY · −15.9% QoQ
- EPS (diluted)
- −$0.69
- −43.7% YoY · −7.8% QoQ
Source: XBRL data from the Tyra Biosciences, Inc. (TYRA) Q2 2026 10-Q on SEC EDGAR. USD.
Tyra Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Equity issuance risk: ATM capacity expanded from fully utilized $150.0 million to up to $250.0 million on August 4, 2026
- Dilution risk: Additional common-stock sales enabled under the amended Sales Agreement
- Insider-trading compliance: Five officers and directors adopted trading arrangements during the quarter
- Executive equity-sale risk: Chief Medical Officer plan authorizes sales of up to 74,000 shares through February 26, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tyra Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.